P Paschka
Overview
Explore the profile of P Paschka including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
710
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Dohner K, Paschka P, Dohner H
Internist (Berl)
. 2015 Mar;
56(4):354-63.
PMID: 25787321
In recent years, the development of novel molecular techniques has been instrumental in deciphering the genetic heterogeneity of acute myeloid leukemia (AML) as well as in gaining important insights into...
12.
Luck S, Russ A, Botzenhardt U, Paschka P, Schlenk R, Dohner H, et al.
Leukemia
. 2011 Jun;
25(11):1728-38.
PMID: 21701487
Core-binding factor (CBF) leukemias, characterized by translocations t(8;21) or inv(16)/t(16;16) targeting the CBF, constitute acute myeloid leukemia (AML) subgroups with favorable prognosis. However, about 40% of patients relapse and the...
13.
Stegelmann F, Bullinger L, Schlenk R, Paschka P, Griesshammer M, Blersch C, et al.
Leukemia
. 2011 May;
25(7):1217-9.
PMID: 21537334
No abstract available.
14.
Burchert A, Wang Y, Cai D, von Bubnoff N, Paschka P, Muller-Brusselbach S, et al.
Leukemia
. 2005 Sep;
19(10):1774-82.
PMID: 16136169
BCR/ABL-kinase mutations frequently mediate clinical resistance to the selective tyrosine kinase inhibitor Imatinib mesylate (IM, Gleevec). However, mechanisms that promote survival of BCR/ABL-positive cells before clinically overt IM resistance occurs...
15.
Ugurel S, Hildenbrand R, Zimpfer A, La Rosee P, Paschka P, Sucker A, et al.
Br J Cancer
. 2005 Apr;
92(8):1398-405.
PMID: 15846297
This two-centre phase-II trial aimed at investigating the efficacy of imatinib in metastasised melanoma patients in correlation to the tumour expression profile of the imatinib targets c-kit and platelet-derived growth...
16.
Demehri S, Paschka P, Schultheis B, Lange T, Koizumi T, Sugimoto T, et al.
Leukemia
. 2005 Feb;
19(4):681-4.
PMID: 15703785
No abstract available.
17.
Muller M, Gattermann N, Lahaye T, Deininger M, Berndt A, Fruehauf S, et al.
Leukemia
. 2003 Oct;
17(12):2392-400.
PMID: 14523462
We sought to determine dynamics of BCR-ABL mRNA expression levels in 139 patients with chronic myelogenous leukemia (CML) in early chronic phase, randomized to receive imatinib (n=69) or interferon (IFN)/Ara-C...
18.
Paschka P, Muller M, Merx K, Kreil S, Schoch C, Lahaye T, et al.
Leukemia
. 2003 Sep;
17(9):1687-94.
PMID: 12970765
A significant proportion of chronic myeloid leukemia (CML) patients achieve a major cytogenetic remission (MCR) to imatinib therapy after failing interferon (IFN) alpha-based protocols. We sought to determine levels of...
19.
Fruehauf S, Topaly J, Schad M, Paschka P, Gschaidmeier H, Zeller W, et al.
J Leukoc Biol
. 2003 Apr;
73(5):600-3.
PMID: 12714574
Chronic myelogenous leukemia (CML) is characterized by aberrant trafficking of malignant hematopoietic progenitor cells in the peripheral blood. Expression of the cell adhesion molecule CD62L was reported to be significantly...
20.
Merx K, Muller M, Kreil S, Lahaye T, Paschka P, Schoch C, et al.
Leukemia
. 2002 Aug;
16(9):1579-83.
PMID: 12200666
The degree of tumor load reduction as measured by cytogenetic response is an important prognostic factor for chronic myelogenous leukemia (CML) patients on therapy. We sought to determine whether BCR-ABL...